GSH rapidly activates DNS-caged alkoxyamines, producing SO 2 and fluorescent alkoxyamines that trap AP sites in live cells
It contains the same active molecule semaglutide, a GLP-1 receptor agonist so the mechanism is the same
The insulin helps lower blood sugar levels, which can be helpful in managing Type 2 diabetes
Specialty and emerging peptides Newer compounds like SS-31 , 5-amino-1MQ , tesofensine , and kisspeptin may have less well-established storage data compared to legacy compounds
A ClinicalTrials.gov study updated April 30, 2026 is recruiting participants to test cosmetic leave-on products for the appearance of gray hair
Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions
